Asarina Pharma (Tourette Syndrome Therapy Compound Rights) Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
1
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) General Information
Description
A neurological compound steroid that modulates the effects of Allopregnanolone.
Contact Information
Corporate Office
- Solna
- Sweden
Corporate Office
- Solna
- Sweden
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) Signals
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Asarina Pharma | Solna, Sweden | 2006 |
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) FAQs
-
When was Asarina Pharma (Tourette Syndrome Therapy Compound Rights) founded?
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) was founded in 2006.
-
Where is Asarina Pharma (Tourette Syndrome Therapy Compound Rights) headquartered?
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) is headquartered in Solna, Sweden.
-
What is the size of Asarina Pharma (Tourette Syndrome Therapy Compound Rights)?
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) has 1 total employees.
-
What industry is Asarina Pharma (Tourette Syndrome Therapy Compound Rights) in?
Asarina Pharma (Tourette Syndrome Therapy Compound Rights)’s primary industry is Buildings and Property.
-
Is Asarina Pharma (Tourette Syndrome Therapy Compound Rights) a private or public company?
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) is a Private company.
-
What is the current valuation of Asarina Pharma (Tourette Syndrome Therapy Compound Rights)?
The current valuation of Asarina Pharma (Tourette Syndrome Therapy Compound Rights) is .
-
What is Asarina Pharma (Tourette Syndrome Therapy Compound Rights)’s current revenue?
The current revenue for Asarina Pharma (Tourette Syndrome Therapy Compound Rights) is .
-
Who are Asarina Pharma (Tourette Syndrome Therapy Compound Rights)’s investors?
Asarina Pharma has invested in Asarina Pharma (Tourette Syndrome Therapy Compound Rights).
-
When was Asarina Pharma (Tourette Syndrome Therapy Compound Rights) acquired?
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) was acquired on 06-Feb-2025.
-
Who acquired Asarina Pharma (Tourette Syndrome Therapy Compound Rights)?
Asarina Pharma (Tourette Syndrome Therapy Compound Rights) was acquired by Relmada Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process